APD-209(APD-209) - _专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点-

作用机制-

治疗领域

肿瘤感染眼部疾病+ [1]

在研适应症-

非在研适应症

腺病毒科感染晚期癌症恶病质+ [1]

原研机构

Adenovir Pharma AB

在研机构-

非在研机构

Acacia Pharma Ltd.

Adenovir Pharma AB

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 APD-209 相关的临床试验

NCT01977443 / Completed临床2期

Evaluation of the Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Acute Phase Adenoviral-Induced Epidemic Keratoconjunctivitis (EKC). A Randomised, Double-Masked, Placebo-Controlled, Multi-Centre Proof-of-Concept Study

A randomized, double-masked, placebo-controlled, multi-centre phase IIa proof-of-concept study to evaluate efficacy and safety of APD-209 Eye drops for treatment of acute phase adenovirus-induced EKC. The aims of the study are to investigate the therapeutic efficacy of APD-209 Eye drops as measured by adenoviral load, time to viral eradication, clinical resolution of EKC (objective and subjective assessments), presence of opacities, visual acuity and frequency of second eye infections, and to assess the safety and tolerability of APD-209 Eye drops in EKC infected eyes.

开始日期2013-11-01

申办/合作机构

Adenovir Pharma AB

[+1]

EUCTR2012-005694-31-SE / Not yet recruitingN/A

Evaluation of the Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Acute Phase Adenoviral-Induced Epidemic Keratoconjunctivitis (EKC). A Randomised, Double-Masked, Placebo-Controlled, Multi-Centre Proof-of-Concept Study - APD-209 Eye drops phase IIa study

开始日期2013-07-05

申办/合作机构

Adenovir Pharma AB

NCT00895726 / Completed临床2期

Open-Label, Pilot Phase I/II Study of the Efficacy and Safety of APD209 in Patients With Cachexia and Advanced Malignancy

Primary Objective:
To assess the efficacy of APD209 in adult patients with active cachexia associated with advanced malignancy and not caused by simple starvation.
Secondary Objective:
To assess the safety of APD209 in patients with advanced malignancy and active cachexia.

开始日期2009-03-01

申办/合作机构

Acacia Pharma Ltd.

100 项与 APD-209 相关的临床结果

登录后查看更多信息

100 项与 APD-209 相关的转化医学

登录后查看更多信息

100 项与 APD-209 相关的专利（医药）

登录后查看更多信息

100 项与 APD-209 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
角结膜炎	临床2期	瑞典	Adenovir Pharma AB	2013-11-01
角结膜炎	临床2期	波兰	Adenovir Pharma AB	2013-11-01
角结膜炎	临床2期	德国	Adenovir Pharma AB	2013-11-01
晚期癌症	临床2期	英国	Acacia Pharma Ltd.	2009-03-01
恶病质	临床2期	英国	Acacia Pharma Ltd.	2009-03-01
腺病毒科感染	临床2期	-	Adenovir Pharma AB	-